

**Supplementary Figure 1.** Solicited local and systemic adverse events reported after primary vaccination in Study 2019nCoV-501 in (A) HIV-negative participants, (B) People living with HIV (PLWH) [24,31]. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

(A) Study 2019nCoV-501 – HIV-negative participants




(B) Study 2019nCoV-501 – PLWH




**Supplementary Figure 2.** Study 2019nCoV-101 immunogenicity of NVX-CoV2373 over time and relative to patients infected with SARS-CoV-2 stratified by clinical presentation [18]. (A) Geometric mean titer IgG response. (B) Geometric mean titer neutralizing antibody response.

(A)



(B)



EU, enzyme-linked immunosorbent assay units; IC>99%, inhibitory concentration >99%; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.